Phase 2b/3 Start

The meeting also validated OKYO Pharma’s Chemistry, Manufacturing and Controls (CMC) strategy and the ocular pain assessment survey (OPAS) used in the protocol. With these elements cleared, the company plans to commence a 120‑patient, multiple‑dose phase 2b/3 study during the first half of 2026.